IL307762A - Vaccine against viruses - Google Patents
Vaccine against virusesInfo
- Publication number
- IL307762A IL307762A IL307762A IL30776223A IL307762A IL 307762 A IL307762 A IL 307762A IL 307762 A IL307762 A IL 307762A IL 30776223 A IL30776223 A IL 30776223A IL 307762 A IL307762 A IL 307762A
- Authority
- IL
- Israel
- Prior art keywords
- amino acid
- virus protein
- modified
- virus
- parental
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims 100
- 229960005486 vaccine Drugs 0.000 title claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 72
- 108090000623 proteins and genes Proteins 0.000 claims 66
- 102000004169 proteins and genes Human genes 0.000 claims 66
- 238000000034 method Methods 0.000 claims 61
- 239000002773 nucleotide Substances 0.000 claims 24
- 125000003729 nucleotide group Chemical group 0.000 claims 24
- 150000001413 amino acids Chemical class 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 19
- 238000012986 modification Methods 0.000 claims 13
- 230000004048 modification Effects 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 108020004705 Codon Proteins 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 238000002255 vaccination Methods 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- -1 amino acid sequence amino acid Chemical class 0.000 claims 2
- 229940022005 RNA vaccine Drugs 0.000 claims 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 108700021021 mRNA Vaccine Proteins 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021060273 | 2021-04-20 | ||
| PCT/EP2022/060417 WO2022223617A1 (en) | 2021-04-20 | 2022-04-20 | Virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307762A true IL307762A (en) | 2023-12-01 |
Family
ID=81579467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307762A IL307762A (en) | 2021-04-20 | 2022-04-20 | Vaccine against viruses |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240383947A1 (https=) |
| EP (1) | EP4326317A1 (https=) |
| JP (1) | JP2024517642A (https=) |
| KR (1) | KR20240009419A (https=) |
| CN (1) | CN117750974A (https=) |
| AU (1) | AU2022260466A1 (https=) |
| BR (1) | BR112023021654A2 (https=) |
| CA (1) | CA3215771A1 (https=) |
| IL (1) | IL307762A (https=) |
| MX (1) | MX2023012368A (https=) |
| WO (1) | WO2022223617A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN117153245B (zh) * | 2023-10-18 | 2024-03-19 | 无锡市疾病预防控制中心 | 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1900753B1 (en) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| WO2009083804A2 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| EA201001734A1 (ru) | 2008-05-02 | 2011-10-31 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP2493871B1 (en) | 2009-10-30 | 2014-09-03 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| EP2558491B1 (en) | 2010-04-13 | 2018-07-04 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
| EP2758436B1 (en) | 2011-09-23 | 2019-06-12 | Universität Stuttgart | Serum half-life extension using immunoglobulin binding domains |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
-
2022
- 2022-04-20 BR BR112023021654A patent/BR112023021654A2/pt not_active Application Discontinuation
- 2022-04-20 WO PCT/EP2022/060417 patent/WO2022223617A1/en not_active Ceased
- 2022-04-20 JP JP2023564119A patent/JP2024517642A/ja active Pending
- 2022-04-20 EP EP22720733.9A patent/EP4326317A1/en active Pending
- 2022-04-20 IL IL307762A patent/IL307762A/en unknown
- 2022-04-20 CN CN202280043287.9A patent/CN117750974A/zh active Pending
- 2022-04-20 US US18/287,608 patent/US20240383947A1/en active Pending
- 2022-04-20 AU AU2022260466A patent/AU2022260466A1/en active Pending
- 2022-04-20 CA CA3215771A patent/CA3215771A1/en active Pending
- 2022-04-20 KR KR1020237039881A patent/KR20240009419A/ko active Pending
- 2022-04-20 MX MX2023012368A patent/MX2023012368A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021654A2 (pt) | 2023-12-26 |
| AU2022260466A9 (en) | 2023-11-16 |
| MX2023012368A (es) | 2023-11-01 |
| CA3215771A1 (en) | 2022-10-27 |
| EP4326317A1 (en) | 2024-02-28 |
| JP2024517642A (ja) | 2024-04-23 |
| US20240383947A1 (en) | 2024-11-21 |
| KR20240009419A (ko) | 2024-01-22 |
| AU2022260466A1 (en) | 2023-11-02 |
| CN117750974A (zh) | 2024-03-22 |
| WO2022223617A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL307762A (en) | Vaccine against viruses | |
| EP1084261B1 (en) | Recombinant venezuelan equine encephalitis virus vaccine | |
| JP2005511076A5 (https=) | ||
| EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
| CN106167518B (zh) | 截短的轮状病毒vp4蛋白及其用途 | |
| CN1653085A (zh) | Hiv调节/辅助蛋白的融合蛋白 | |
| KR102777995B1 (ko) | 11형 인유두종 바이러스 엘1 단백질의 돌연변이체 | |
| US20250339511A1 (en) | Nucleic acid vaccine against monkeypox virus and use thereof | |
| WO2011062625A2 (en) | Physicochemical (pcp) based consensus sequences and uses thereof | |
| JP2024517642A5 (https=) | ||
| WO2011150745A1 (zh) | 结核杆菌ag85ab嵌合基因疫苗、其制备方法及应用 | |
| KR20200070302A (ko) | 치주염 백신 및 관련 조성물 및 사용 방법 | |
| CN103890004A (zh) | 由具有特定免疫显性表位的婴儿利什曼虫pfr1蛋白片段组成的嵌合分子可用于抗利什曼病的免疫疗法 | |
| EP4317176A1 (en) | Attenuated reovirus-based vaccine composition and use thereof | |
| KR102675879B1 (ko) | SARS-CoV-2 스파이크 단백질 S1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도 | |
| KR20240009981A (ko) | 아미노산, 뉴클레오티드 및 이를 발현하는 벡터, 및 사르베코바이러스 감염을 예방하는 데에 있어서의 이의 용도 | |
| WO1992003553A1 (en) | Footrot vaccine | |
| WO2002018600A1 (en) | Groes and groel homologs of francisella tularensis | |
| KR100430960B1 (ko) | 매우약독화된재조합일본뇌염바이러스를생성하는감염성일본뇌염바이러스cDNA클론및이의백신 | |
| WO2003102025A1 (en) | Protein inducing cell death of helicobacter pylori | |
| JP2024518565A (ja) | 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤 | |
| JPH08198774A (ja) | Ｄｎａワクチン | |
| CN118019754A (zh) | 诱导pres特异性中和抗体的hbv疫苗 | |
| WO2023212658A3 (en) | Compositions for the treatment of infectious disease related complications and methods thereof | |
| US20160215023A1 (en) | Simple vaccines from dna launched suicidal flaviviruses |